Controversial Shift: U.S. Panel Reverses Newborn Hepatitis B Vaccine Recommendation

A U.S. advisory committee has removed the broad recommendation for newborn hepatitis B vaccination, igniting debate among health experts. Critics argue the decision lacks data and risks children's health, while supporters advocate for shared decision-making. Established medical organizations are expected to maintain their stance on recommending the vaccine.

In a significant policy shift, a group of advisers to Health Secretary Robert F. Kennedy Jr. has voted to drop the broad recommendation for newborn hepatitis B vaccination. The move marks a major change in vaccine policy under Kennedy's tenure.

Critics, including Dorit Reiss, a vaccine law expert, have voiced concerns about the decision, citing a lack of hepatitis B expertise on the committee. Dr. Cody Meissner, a committee member, criticized the vote, arguing it introduces risk and confusion.

Despite the committee's decision, major health organizations like the American Academy of Pediatrics are likely to maintain their recommendation of the hepatitis B vaccine at birth. The debate underscores tensions between shared decision-making and established public health policy.